Thalidomide in agnogenic and secondary myelofibrosis

Letizia Canepa, Filippo Ballerini, Riccardo Varaldo, Sabrina Quintino, Lizia Reni, Marino Clavio, Maurizio Miglino, Ivana Pierri, Marco Gobbi

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Myelofibrosis with myeloid metaplasia (MMM) is a clonal disorder involving disregulation of angiogenesis and immunomodulatory mechanisms. Thalidomide (Thal) retains antiangiogenic, immunomodulatory and cytokine regulatory properties and recently it has been used successfully in multiple myeloma. Here, we report our experience in 10 MMM patients treated with Thal. Patients with agnogenic MMM treated in an early phase of the disease obtained significant benefits from the therapy and remain transfusion-free. In contrast, all secondary MMM failed to respond. These preliminary findings confirm that Thal plays a role in MMM therapy, although the efficacy in the different phases of the disease must be further evaluated.

Original languageEnglish
Pages (from-to)313-315
Number of pages3
JournalBritish Journal of Haematology
Volume115
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

Primary Myelofibrosis
Thalidomide
Multiple Myeloma
Cytokines
Therapeutics

Keywords

  • Antiangiogenesis
  • Myelofibrosis
  • Myeloproliferative disorders
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Cite this

Thalidomide in agnogenic and secondary myelofibrosis. / Canepa, Letizia; Ballerini, Filippo; Varaldo, Riccardo; Quintino, Sabrina; Reni, Lizia; Clavio, Marino; Miglino, Maurizio; Pierri, Ivana; Gobbi, Marco.

In: British Journal of Haematology, Vol. 115, No. 2, 2001, p. 313-315.

Research output: Contribution to journalArticle

Canepa, Letizia ; Ballerini, Filippo ; Varaldo, Riccardo ; Quintino, Sabrina ; Reni, Lizia ; Clavio, Marino ; Miglino, Maurizio ; Pierri, Ivana ; Gobbi, Marco. / Thalidomide in agnogenic and secondary myelofibrosis. In: British Journal of Haematology. 2001 ; Vol. 115, No. 2. pp. 313-315.
@article{7148c9f9a8214d829da6252fa0e2d5f9,
title = "Thalidomide in agnogenic and secondary myelofibrosis",
abstract = "Myelofibrosis with myeloid metaplasia (MMM) is a clonal disorder involving disregulation of angiogenesis and immunomodulatory mechanisms. Thalidomide (Thal) retains antiangiogenic, immunomodulatory and cytokine regulatory properties and recently it has been used successfully in multiple myeloma. Here, we report our experience in 10 MMM patients treated with Thal. Patients with agnogenic MMM treated in an early phase of the disease obtained significant benefits from the therapy and remain transfusion-free. In contrast, all secondary MMM failed to respond. These preliminary findings confirm that Thal plays a role in MMM therapy, although the efficacy in the different phases of the disease must be further evaluated.",
keywords = "Antiangiogenesis, Myelofibrosis, Myeloproliferative disorders, Thalidomide",
author = "Letizia Canepa and Filippo Ballerini and Riccardo Varaldo and Sabrina Quintino and Lizia Reni and Marino Clavio and Maurizio Miglino and Ivana Pierri and Marco Gobbi",
year = "2001",
doi = "10.1046/j.1365-2141.2001.03072.x",
language = "English",
volume = "115",
pages = "313--315",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "2",

}

TY - JOUR

T1 - Thalidomide in agnogenic and secondary myelofibrosis

AU - Canepa, Letizia

AU - Ballerini, Filippo

AU - Varaldo, Riccardo

AU - Quintino, Sabrina

AU - Reni, Lizia

AU - Clavio, Marino

AU - Miglino, Maurizio

AU - Pierri, Ivana

AU - Gobbi, Marco

PY - 2001

Y1 - 2001

N2 - Myelofibrosis with myeloid metaplasia (MMM) is a clonal disorder involving disregulation of angiogenesis and immunomodulatory mechanisms. Thalidomide (Thal) retains antiangiogenic, immunomodulatory and cytokine regulatory properties and recently it has been used successfully in multiple myeloma. Here, we report our experience in 10 MMM patients treated with Thal. Patients with agnogenic MMM treated in an early phase of the disease obtained significant benefits from the therapy and remain transfusion-free. In contrast, all secondary MMM failed to respond. These preliminary findings confirm that Thal plays a role in MMM therapy, although the efficacy in the different phases of the disease must be further evaluated.

AB - Myelofibrosis with myeloid metaplasia (MMM) is a clonal disorder involving disregulation of angiogenesis and immunomodulatory mechanisms. Thalidomide (Thal) retains antiangiogenic, immunomodulatory and cytokine regulatory properties and recently it has been used successfully in multiple myeloma. Here, we report our experience in 10 MMM patients treated with Thal. Patients with agnogenic MMM treated in an early phase of the disease obtained significant benefits from the therapy and remain transfusion-free. In contrast, all secondary MMM failed to respond. These preliminary findings confirm that Thal plays a role in MMM therapy, although the efficacy in the different phases of the disease must be further evaluated.

KW - Antiangiogenesis

KW - Myelofibrosis

KW - Myeloproliferative disorders

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=0035726548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035726548&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2001.03072.x

DO - 10.1046/j.1365-2141.2001.03072.x

M3 - Article

VL - 115

SP - 313

EP - 315

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -